Brought to you by 
FOPO nets $6.3mm for Heat Biologics
28 Mar 2016
Executive Summary
Immuno-oncology firm Heat Biologics Inc. netted $6.3mm through the follow-on public offering of 9.1mm common shares at $0.75 each. The company also issued five-year warrants to purchase another 6.8mm shares at an exercise price of $1 per whole share. (Each warrant entitles the holder to buy 0.75 of a share.) Heat will use some of the proceeds to finish up a Phase II trial of HS410 for non-muscle invasive bladder cancer, and other funds will support a Phase Ib study of HS110 in non-small cell lung cancer.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
FOPO nets $6.3mm for Heat Biologics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice